Elizabeth L. Hougen

CIK: 0001074773

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (33.3%)

Position reduction

Option Exercises (M)7 (25.9%)

Derivative conversions

Awards (A)11 (40.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARTV

Artiva Biotherapeutics, Inc.

Director

IONS

IONIS PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (27 total)

ARTV
Artiva Biotherapeutics, Inc.
Sep 10, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
16.3K shares-
ARTV
Artiva Biotherapeutics, Inc.
Sep 8, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
13.8K shares-
IONS
IONIS PHARMACEUTICALS INC
Mar 17, 2026
Sale(S)
Direct
10.2K shares at avg. $73.21$745K
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Sale(S)
Direct
9.4K shares at avg. $72.77$687K
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Exercise(M)
Direct
33.1K shares at avg. $32.60$1.1M
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Exercise(M)
Direct
20.5K shares at avg. $37.58$772K
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Sale(S)
Direct
205.6K shares at avg. $72.38$14.9M
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Exercise(M)
Direct
60.3K shares at avg. $60.89$3.7M
IONS
IONIS PHARMACEUTICALS INC
Mar 16, 2026
Exercise(M)
Direct
61K shares at avg. $56.78$3.5M
IONS
IONIS PHARMACEUTICALS INC
Jan 30, 2026
Sale(S)
Direct
7K shares at avg. $83.24$582K
IONS
IONIS PHARMACEUTICALS INC
Jan 29, 2026
Award(A)
Direct
13.6K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 16, 2026
Sale(S)
Direct
12.9K shares at avg. $75.22$972K
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2026
Exercise(M)
Direct
28.7K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2026
Award(A)
Restricted Stock Unit
Direct
12.9K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2026
Award(A)
Performance Restricted Stock Units
Direct
34.4K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 2, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
25.8K shares-
IONS
IONIS PHARMACEUTICALS INC
Sep 30, 2025
Exercise(M)
Direct
49.8K shares at avg. $53.77$2.7M
IONS
IONIS PHARMACEUTICALS INC
Sep 30, 2025
Sale(S)
Direct
49.8K shares at avg. $65.26$3.2M
ARTV
Artiva Biotherapeutics, Inc.
Jun 24, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
13.8K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 31, 2025
Sale(S)
Direct
1.5K shares at avg. $32.44$49K
IONS
IONIS PHARMACEUTICALS INC
Jan 30, 2025
Award(A)
Direct
4.1K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 16, 2025
Sale(S)
Direct
8.9K shares at avg. $32.81$291K
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2025
Exercise(M)
Direct
23.9K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2025
Award(A)
Restricted Stock Unit
Direct
46.5K shares-
IONS
IONIS PHARMACEUTICALS INC
Jan 15, 2025
Award(A)
Performance Restricted Stock Units
Direct
31K shares-

		Type	Shares	Price		Ownership
Sep 10, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	16,250	-	-	Direct
Sep 8, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	13,750	-	-	Direct
Mar 17, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	10,172	$73.21	$744,662	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	9,440	$72.77	$686,902	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	33,118	$32.60	$1,079,647	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	20,541	$37.58	$771,931	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	205,608	$72.38	$14,882,113	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	60,299	$60.89	$3,671,606	Direct
Mar 16, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	61,041	$56.78	$3,465,908	Direct
Jan 30, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	6,988	$83.24	$581,702	Direct
Jan 29, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A)	13,562	-	$0	Direct
Jan 16, 2026	IONS IONIS PHARMACEUTICALS INC	Sale(S)	12,922	$75.22	$971,993	Direct
Jan 15, 2026	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	28,729	-	$0	Direct
Jan 15, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	12,885	-	-	Direct
Jan 15, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Performance Restricted Stock Units	34,360	-	-	Direct
Jan 2, 2026	IONS IONIS PHARMACEUTICALS INC	Award(A) Non-Qualified Stock Option (right to buy)	25,770	-	-	Direct
Sep 30, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	49,800	$53.77	$2,677,746	Direct
Sep 30, 2025	IONS IONIS PHARMACEUTICALS INC	Sale(S)	49,800	$65.26	$3,249,734	Direct
Jun 24, 2025	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	13,750	-	-	Direct
Jan 31, 2025	IONS IONIS PHARMACEUTICALS INC	Sale(S)	1,523	$32.44	$49,404	Direct
Jan 30, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A)	4,138	-	-	Direct
Jan 16, 2025	IONS IONIS PHARMACEUTICALS INC	Sale(S)	8,870	$32.81	$290,989	Direct
Jan 15, 2025	IONS IONIS PHARMACEUTICALS INC	Exercise(M)	23,887	-	$0	Direct
Jan 15, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Restricted Stock Unit	46,500	-	-	Direct
Jan 15, 2025	IONS IONIS PHARMACEUTICALS INC	Award(A) Performance Restricted Stock Units	31,000	-	-	Direct

1-25 of 27 transactions

About HOUGEN ELIZABETH L

HOUGEN ELIZABETH L (SEC CIK 0001074773) files insider reports with the SEC as Director of Artiva Biotherapeutics, Inc. (ARTV) and EVP, Finance & CFO of IONIS PHARMACEUTICALS INC (IONS).

Signal8 holds 12 ownership filings by HOUGEN ELIZABETH L, all Form 4s, filed between Sep 4, 2024 and Sep 14, 2026. Those filings report 27 transactions, from Feb 2, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on HOUGEN ELIZABETH L's filings is in SAN DIEGO, CA.

Recent filings by HOUGEN ELIZABETH L

Sep 10, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
Sep 8, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
Mar 17, 2026: Open-market sale of IONS shares (Form 4, code S).
Mar 16, 2026: Open-market sale of IONS shares (Form 4, code S).
Mar 16, 2026: Option exercises of IONS shares (2 lines, Form 4, code M).

Other insiders filing for Artiva Biotherapeutics, Inc. (ARTV)

Horan Christopher, Chief Tech Operations Officer
Bush Jennifer, COO, CLO, Compliance Officer
Banerjee Subhashis, Chief Medical Officer
Aslan Fred, Chief Executive Officer
RA CAPITAL MANAGEMENT, L.P., Director
Stoppel Laura, Director

How to read Form 4 transaction codes